iiinova — where your digital self keeps evolving

BioVie Inc @biovie.bsky.social · 15/09/2026

Today, we announced positive results from our Phase 2 signal finding ADDRESS-LC trial evalulating bezisterim for the treatment of neurological symptoms associated with #LongCOVID. Read: investors.bioviepharma.com/news/news-de...

13711

BioVie Inc @biovie.bsky.social · 14/09/2026

BioVie will host a conference call and webcast tomorrow, Tuesday, September 15, at 8:30am ET to discuss topline results from the Phase 2 ADDRESS-LC trial evaluating its investigational drug candidate bezisterim in #LongCOVID. Register: lifescievents.com/event/bkvp81/ #ClinicalUpdate

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long COVID

Tuesday, September 15, 2026 at 8:30 a.m. ET

010

BioVie Inc @biovie.bsky.social · 08/09/2026

Today, BioVie announced the next stage of engagement with the U.S. Food and Drug Administration (FDA) to advance the Phase 3 development program evaluating bezisterim in Parkinson’s disease. Read more: investors.bioviepharma.com/news/news-de... #ParkinsonsDisease

PARKINSON’S UPDATE

BioVie Announces Update to Parkinson’s Phase 3 Development Program

011

BioVie Inc @biovie.bsky.social · 31/08/2026

Today, BioVie announced that the last on-treatment patient visit in the ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of #LongCOVID has been completed. Read more: investors.bioviepharma.com/news/news-de...

LONG COVID UPDATE
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

110

BioVie Inc @biovie.bsky.social · 06/08/2026

Today, we announced positive topline results from the Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage #Parkinson’s disease. The trial successfully met prespecified endpoints. Learn more here: investors.bioviepharma.com/news/news-de...

110

BioVie Inc @biovie.bsky.social · 31/07/2026

🧠 Brain fog. 🥱 Fatigue. 🤕 Cognitive impairment. For the millions living with Long COVID, these neurological and neuropsychiatric symptoms are among the most common, chronic, and debilitating. And still without a single FDA-approved treatment. #Neuroinflammation #LongCOVID

Graphic shows images of three people - from left:
1. A man with his eyes closed and his fingers pressed to his eyes. The words “Brain fog” appear in the middle of the frame.
2. A woman with her eyes closed, leaning on her hand. The word “Fatigue” appears in the middle of the frame.
3. A man with a furrowed brow looking off in the distance. The words “Cognitive impairment” appear in the middle of the frame.

Copy in right bottom section reads:
For the millions living with Long COVID, these neurological and neuropsychiatric symptoms are among the most common, chronic, and debilitating.

010

BioVie Inc @biovie.bsky.social · 23/07/2026

#ParkinsonsDisease is the fastest-growing neurodegenerative disorder in the world. Most people think of it primarily as a movement disorder: tremors & motor symptoms. The reality is far more complex. #WorldBrainDay

Graphic headline:
Non-motor symptoms associated with Parkinson’s disease
on the left is an image of a brain
Copy on the right reads:
- Cognitive decline
- Depression
- Sleep dysfunction
- Fatigue
- Autonomic disruption

110

BioVie Inc @biovie.bsky.social · 14/07/2026

Findings from @parkinsondotorg.bsky.social's 2026 State of the Community Survey shows what matters most to ppl affected by #Parkinson's: 52% identified non-movement symptoms - sleep disturbances, mood changes & cognitive challenges - among the most pressing concerns, alongside movement symptoms.

A PDF graphic, FULL DETAILS and DESCRIPTION of the graphic can be found on Parkinson’s Foundation website here: https://www.parkinson.org/advancing-research/survey-data/community-survey

000

BioVie Inc @biovie.bsky.social · 10/07/2026

Today is #ChronicDiseaseAwarenessDay and Long COVID is a condition that demands our attention. BioVie is committed to advancing research for the millions navigating life with chronic conditions like #LongCOVID.

According to the CDC, Long COVID is defined as a chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months.

162

BioVie Inc @biovie.bsky.social · 29/06/2026

A new @jama.com study found that the number of people suffering with #longCOVID may be double current estimates. These rates translate to more than 18M Americans, and reflect the growing burden of chronic conditions following COVID-19 infection. #PASC #Neuroinflammation #BrainAwarenessMonth

Left side of graphic shows a map of the U.S. with 5 blue icons of a person and larger white icon
The copy on the right reads:
According to new research, about 1 in 6 American adults who tested positive for COVID-19 developed long COVID
More than twice the rate previously estimated

082

BioVie Inc @biovie.bsky.social · 23/06/2026

Parkinson's is the second most common neurodegenerative disease after Alzheimer's disease. #Inflammation and insulin resistance are believed to be key drivers of both #ParkinsonsDisease and Alzheimer's. #AlzheimersBrainAwarenessMonth #NeuroSky

Left side of graphic shows an icon of a brain in light blue
Right side copy reads: Parkinson’s is the #2 most common neurodegenerative disease

011

BioVie Inc @biovie.bsky.social · 17/06/2026

There are no approved treatments for #LongCOVID - yet millions are living with persistent brain fog, fatigue & cognitive impairment driven by neuroinflammation. BioVie's ADDRESS-LC trial is fully enrolled with data expected later this year. #BrainAwarenessMonth

Headline at top of graphic reads: Common symptoms associated with Long Covid
Below on the left is an image of a brain.
On the right is a list of the common symptoms associated with Long Covid:
-Brain fog
-Fatigue
-Cognitive impairment
-Malaise
-Headache
-Sleep disturbances
-Sensory disturbances (numbness, tingling)

010

BioVie Inc @biovie.bsky.social · 11/06/2026

1 in 5 women and 1 in 10 men will develop Alzheimer's in their lifetime. More than 12M Americans are providing unpaid care right now, and the toll on patients, families, and caregivers is profound. #AlzheimersBrainAwarenessMonth #EndALZ

000

BioVie Inc @biovie.bsky.social · 29/05/2026

Nearly 1M Americans are living with #ParkinsonsDisease, with ~ 90K new diagnoses every year. The burden on patients, caregivers, and the healthcare system is immense and will continue to grow. #OlderAmericansMonth

Left copy reads:
May is OLDER AMERICANS MONTH

Alzheimer’s disease affects more than 7 million Americans
-By 2060, the number is projected to nearly double to ~14 million

There are ~1 million Americans living with Parkinson’s disease
-By 2037 the estimated prevalence is 1.6+ million

Image on the right shows two people holding hands (one appears to be child and the other is older)

151

BioVie Inc @biovie.bsky.social · 29/05/2026

#ICYMI: We held a KOL event to discuss how bezisterim’s MoA - targeting #inflammation & insulin resistance in the brain - addresses the pathology & progression of #Parkinson’s disease. Watch the replay here: youtu.be/v8BGmeVvfm0

youtu.be

Virtual KOL Event to Discuss Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease

YouTube video by BioVie Inc

020

BioVie Inc @biovie.bsky.social · 26/05/2026

Enrollment is complete in our Phase 2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected in late summer 2026. Learn more: investors.bioviepharma.com/news/news-de...

LONG COVID UPDATE
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

1115

BioVie Inc @biovie.bsky.social · 18/05/2026

BioVie announced today that the last patient evaluation visit has been completed for our SUNRISE-PD Phase 2 trial evaluating bezisterim in early- stage #Parkinson’s disease. Topline data results are expected in Q3 2026. Read more: investors.bioviepharma.com/news/news-de... #Neurology #NeuroSky

Parkinson’s Update
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease

121

BioVie Inc @biovie.bsky.social · 14/05/2026

During our KOL event last week, Dr. Suzanne de la Monte joined BioVie management to discuss how bezisterim’s MoA addresses the pathology + progression of neurodegenerative disease, including #Parkinson’s disease. Watch the replay: vimeo.com/1190256139/6... #Neuroinflammation #InsulinResistance

vimeo.com

26_05_07_BioVie

This is "26_05_07_BioVie" by T5 Live on Vimeo, the home for high quality videos and the people who love them.

121

BioVie Inc @biovie.bsky.social · 12/05/2026

On #CINDAwareness Day we raise awareness & support those battling #MEcfs, #LongCOVID, #Parkinson’s, #Alzheimer's, & other Chronic Immunological and Neurological Diseases. BioVie is committed to advancing potential treatments for chronic neurological disorders. #NeuroSky 💙💚💜

Graphic with dark blue background on left.
At top is an awareness ribbon in 3 colors: purple, green and blue. Copy below in white reads: International Awareness Day for Chronic Immunological and Neurological Diseases
Thin blue line below and “May 12”
On the right side is an image of a brain

010

BioVie Inc @biovie.bsky.social · 27/04/2026

BioVie is hosting a virtual KOL event on May 7 to discuss the P2 study of bezisterim in #Parkinson's disease ahead of upcoming topline data readout. Information & registration details here: lifescievents.com/event/psk38d0/ #Inflammation #InsulinResistance #Neurosky #Neurology

BioVie to Host KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease ahead of Topline Data in 2Q26

WHEN Thursday, May 7, 2026 at 2:00 p.m. EST

WHO Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical Schook, Providence VA Medical Center) & BioVie management

010

BioVie Inc @biovie.bsky.social · 15/04/2026

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of Parkinson’s Disease at the upcoming #AANAM in Chicago. Details here: investors.bioviepharma.com/news/news-de... #ParkinsonsDisease #ScientificExchange #Neurology #NeuroSky

TOP: American Academy of Neurology 2026 Annual Meeting
LEFT: PRESENTATION April 20, 2026
RIGHT:
Abstract Title:
A Study of NE3107 (Bezisterim) in Early Parkinson’s Disease (SUNRISE-PD): Baseline Demographics and Characteristics

Authors: J. Palumbo, C. Ahlem, C.L. Reading, S. O’Quinn, J. Zhang, M. Stacy)

010

BioVie Inc @biovie.bsky.social · 13/04/2026

We stand with the millions of people living with Parkinson’s to help raise awareness, education, & hope for this progressive neurodegenerative disease that impacts movement, cognition & quality of life. #ParkinsonsAwarenessMonth #ParkinsonsResearch #HopeForPD

010

BioVie Inc @biovie.bsky.social · 09/04/2026

Dopamine is one of the most common terms associated with Parkinson’s because it helps mediate smooth, controlled muscle movements. Yet when levels in the brain are too low, motions may become slow, shaky, and halted. Why? #ParkinsonsDiseaseAwarenessMonth

GRAPHIC with copy on the left that reads:
In Parkinson’s disease brain signals get stuck in traffic.
Inflammation and insulin resistance can disrupt dopamine signaling in the brain. BioVie is advancing research to target inflammation and insulin resistance in the brain to address neurological diseases, including Parkinons’s disease.
On the right is a drawing of a brain with a few cars and traffic lights to illustrate the disruption of dopamine signaling.

110

BioVie Inc @biovie.bsky.social · 02/04/2026

During #ParkinsonsAwarenessMonth we honor people living with PD and their family, friends, nurses, & doctors who stand with them. BioVie is proud to support the Parkinson’s community and is committed to advancing innovative therapies for neurological disorders, including PD.

010

BioVie Inc @biovie.bsky.social · 30/03/2026

To all the physicians conducting research, testing new therapies, treating patients, and providing support for people with #neurological & #neurodegenerative diseases & disorders, on #NationalDoctorsDay, we say THANK YOU. #Alz #Parkinsons #longCOVID #Medsky 🩵🩺

030

BioVie Inc @biovie.bsky.social · 26/03/2026

#Parkinson’s affects ~1M people in the U.S. w/ prevalence expected to rise with aging population. Yet treatment has changed little in 50 years. Our lead drug candidate, bezisterim (NE3107), addresses the underlying neurodegeneration by targeting #inflammation that causes insulin resistance. Read ⬇️

proactiveinvestors.com

BioVie targets Parkinson’s at its source with lead drug bezisterim

For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease’s hallmark motor...

020

BioVie Inc @biovie.bsky.social · 17/03/2026

Some of the most challenging #neurological conditions of our time share a common biology with evidence pointing to #inflammation & insulin resistance as mechanisms underlying #Alzheimer’s, #Parkinson's, & #LongCOVID. #BrainAwarenessWeek

Graphic of a brain
BRAIN AWARENESS WEEK
March 16-22, 2026

120

BioVie Inc @biovie.bsky.social · 16/03/2026

On #LongCOVIDAwarenessDay, we recognize the millions of people still living with the debilitating effects - including #neurological symptoms such as brain fog and fatigue - long after their initial COVID-19 infection.

152

BioVie Inc @biovie.bsky.social · 12/03/2026

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of #Parkinson’s at the upcoming #ADPD2026 annual meeting in Copenhagen. Details here: investors.bioviepharma.com/news/news-de... #ScientificExchange #Neurology #Neuroscience $BIVI

AD/PD 2026
Advances in Science & Therapy
Presentation March 19, 2026

Abstract Title:
Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD)

Authors: Joseph M. Palumbo; Clarence Ahlem; Christopher L. Reading; Stephen O’Quinn; Jeffrey Zhang; Mark Stacy

010

BioVie Inc @biovie.bsky.social · 10/03/2026

Many of the most common #longCOVID symptoms are neurological - #fatigue, #brainfog, cognitive slowing, and memory decline. Research indicates that lingering #inflammation & #biological changes associated with accelerated #aging may be driving these effects in some patients.

bloomberg.com

How Covid Quietly Rewires the Brain

Researchers keep discovering more about the long-term neurological effects of SARS-CoV-2.

020

BioVie Inc @biovie.bsky.social · 03/03/2026

A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim’s effects on #inflammation and insulin resistance, two key drivers of #Alzheimer’s, #Parkinson’s, and #LongCOVID. Register here: www.redchip.com/webinar/BIVI... #Neuroscience $BIVI

REMINDER
BioVie to Host Live Investor Webinar and Q&A on
Wednesday, March 4 at 4:15 p.m. ET

010

BioVie Inc @biovie.bsky.social · 24/02/2026

Our CMO, Dr. Joseph Palumbo joined The Innovators Podcast to discuss BioVie’s mission to develop new treatments for #neurological & #neurodegenerative disorders & what it takes to bring a drug from idea to clinic. Listen here: open.spotify.com/episode/1UZX... #Parkinsons #LongCOVID #Alz

open.spotify.com

The Innovators Podcast - Joseph Palumbo MD - Chief Medical Officer of BioVie

Spotify video

020

BioVie Inc @biovie.bsky.social · 23/02/2026

Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on Wednesday, March 4. Register here: investors.bioviepharma.com/news/news-de... #Alzheimers #Parkinsons #LongCOVID #Neuroinflammation #InsulinResistance $BIVI

CORPORATE UPDATE
BioVie to Host Live Investor Webinar and Q&A on Wednesday, March 4

000

BioVie Inc @biovie.bsky.social · 20/02/2026

Behind every person living with a neurological disease or disorder is a network of caregivers: family, friends, professionals, & advocates who provide essential support. On #NationalCaregiversDay, and every day, we recognize the critical role they play and say THANK YOU! #Alz #Parkinsons #LongCOVID

Image of two people holding hands with the words Thank you Caregivers

000

BioVie Inc @biovie.bsky.social · 17/02/2026

While the higher reported symptom burden in the U.S. may reflect lower stigma and greater access to neurological and mental healthcare rather than more severe disease, #brainfog and #fatigue were among the most common neurological symptoms across all countries. #LongCOVID

000

BioVie Inc @biovie.bsky.social · 12/02/2026

#Parkinson’s care has focused on dopamine for decades. BioVie ($BIVI) is testing a different angle: targeting brain inflammation + insulin resistance. Phase 2 SUNRISE-PD enrollment complete with topline data expected Apr/May 2026. Multiple 2026 catalysts ahead. #Biotech #BIVI

proactiveinvestors.com

BioVie could offer first new Parkinson’s therapy in decades

In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc...

000

BioVie Inc @biovie.bsky.social · 12/02/2026

BioVie announced the acceptance of two abstracts from studies on our lead candidate bezisterim, in the treatment of #Alzheimer’s & #LongCOVID at the upcoming 2026 American College of Psychiatrists (ACP) annual meeting. Read: investors.bioviepharma.com/news/news-de... #ScientificExchange #BIVI

American College of Psychiatrists Annual Meeting Poster Presentations
February 18, 2026

Abstract Title: Bezisterim-Associated Anti-inflammatory
Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer's Disease
Authors: Joseph M. Palumbo; Christopher L. Reading;
Jiayan Yan, Clarence Ahlem; Penelope Markham;
Stephen O'Quinn; Varun B. Dwaraka

Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)
Authors: Joseph M. Palumbo; Penelope Markham; Michael Peluso;
Igor J. Koralnik; Sherry Hsiang-Yi Chou; Lisa McCorkell; Chantal Petit;
Stephen O'Quinn; Chris Reading; Clarence Ahlem; Jiayan Yan

021

BioVie Inc @biovie.bsky.social · 03/02/2026

BioVie’s current P2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms associated with #LongCOVID was designed to address the unmet needs of the community and made possible with support from @solveme.bsky.social & @patientled.bsky.social.

110

BioVie Inc @biovie.bsky.social · 27/01/2026

Enrollment in BioVie’s Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease was made possible with the support of leading advocacy organizations.

Advancing Science with Support from Advocacy Partners
THANK YOU
Logos for:
The Michael J. Fox Foundation for Parkinson's Research
Davis Phinney Foundation for Parkinson's
Parkinson's Foundation

110

Reposted by BioVie Inc

Patient-Led Research Collaborative @patientled.bsky.social · 30/12/2025

Clinical Trials & Pharma Engagement: • Worked with @biovie.bsky.social on study design & recruitment for their Bezisterim trial for #LongCovid, an investigational drug that has shown promise in neurodegenerative conditions. /5

121

BioVie Inc @biovie.bsky.social · 09/01/2026

Our CEO, Cuong Do, spoke with @charlespiller.bsky.social about patterns of alleged misconduct at certain South Florida clinical trial sites, and the devastating implications for the Alzheimer’s community- from patients & families to researchers & drug developers seeking to make a difference.

020

BioVie Inc @biovie.bsky.social · 08/01/2026

Enrollment is complete in our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease. Topline results expected in 1H 2026. Learn more: investors.bioviepharma.com/news/news-de... #Neurology #BIVI

Parkinson's Update
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease

020

BioVie Inc @biovie.bsky.social · 19/12/2025

A study published in @natimmunol.nature.com provides additional evidence that #LongCOVID is associated with chronic #inflammation & metabolic dysregulation. The findings align w/ the MoA of bezisterim, which targets upstream immune signaling involved in chronic inflammation. #BrainFog #Fatigue

“Bezisterim has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID, that also play a key role in neurodegenerative diseases of aging, like Parkinson’s and Alzheimer’s.”

-Cuong Do
President & CEO, BioVie

160

BioVie Inc @biovie.bsky.social · 18/12/2025

Our CEO, Cuong Do, provided an update on the company’s lead candidate bezisterim currently in clinical trials for patients with #Parkinsons’s & #longCOVID. Learn about clinical & regulatory catalysts in 2026 www.youtube.com/watch?v=_RI6... #Neuroinflammation #InsulinResistance #Neuroscience

youtube.com

BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026

YouTube video by Proactive Investors

031

BioVie Inc @biovie.bsky.social · 11/12/2025

On a recent episode of Power to the Patients, our CMO Dr. Joseph Palumbo discussed why #inflammation is emerging as a critical factor in treating #neurodegenerative diseases like #Alzheimer's & #Parkinson's. Listen here: www.youtube.com/watch?v=LNXV... #Neuroscience #InsulinResistance #LongCOVID

youtube.com

Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo

YouTube video by Power to the Patients

030

BioVie Inc @biovie.bsky.social · 05/12/2025

On a recent episode of Power to the Patients podcast, our CEO Cuong Do shares how BioVie is focused on the role of #inflammation & #insulinresistance, key drivers of #Alzheimer’s, #Parkinson’s, & #LongCOVID. Listen here: bit.ly/3Kdr6nE Watch: lnkd.in/gCxPufWc #ClinicalTrials

“GREAT TRIALS are testing a hypothesis or have endpoints that can be observed very objectively with quantifiable metrics. That’s the number one criteria. Second, you try to minimize variability. This is where your inclusion and exclusion criteria are critical. And then of course, you’ve got to have the right people out there executing your trial.”

-Cuong Do
President & CEO, BioVie

030

BioVie Inc @biovie.bsky.social · 04/12/2025

BioVie is proud to announce that our CFO Wendy Kim was selected as a winner of the Third Annual Women CFOs of the Year Awards by the @feisv.bsky.social chapter honoring outstanding finance leaders for their achievements. bit.ly/4rBiQP3 #LifeSciences #BiotechLeadership

CONGRATULATIONS!
Wendy Kim
Honored in FEI Silicon Valley Chapter Women CEO of the Year Awards

Photo of Wendy Kim
Chief Financial Officer, BioVie

021

BioVie Inc @biovie.bsky.social · 25/11/2025

This month we honor those living with #Alzheimer’s and the families, clinicians, & researchers supporting them. And THANK YOU to the millions of #caregivers providing essential, heartfelt assistance to loved ones with #neurodegenerative disorders. #AlzheimersDiseaseAwareness #FamilyCaregiversMonth

November

National FAMILY CAREGIVERS Month
and
National ALZHEIMER'S DISEASE AWARENESS Month

Image of a heart with two hands inside attached to a ribbon

020

BioVie Inc @biovie.bsky.social · 19/11/2025

We’re at #LongCOVIDIntl 2025 presenting our ongoing P2 ADDRESS-LC trial evaluating the efficacy, safety, & tolerability of bezisterim in participants with #LongCOVID enriched for #BrainFog & #fatigue. Learn about the currently enrolling trial: www.addresslongcovid.com @academicmededu.bsky.social

LONG COVID UPDATE

BioVie Presents at 3rd Long COVID International Conference 2025
November 19-20, 2025

A Phase 2 Trial Designed to Enhance Signal Detection in an Evaluation of Bezisterim (NE3107) for the Treatment of Neurological Symptoms of Long COVID

063

BioVie Inc @biovie.bsky.social · 31/10/2025

Earlier this month our CEO held a virtual investor webinar to discuss bezisterim for the treatment of neurological & neurodegenerative diseases. Catch the replay here: www.youtube.com/watch?v=ts_1... #Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI

REPLAY AVAILABLE
Investor Webinar and Q&A
Cuong Do
President & CEO, BioVie

030